Global University Venturing

The corporate has donated $200,000 to bring University of Michigan philanthropic seed fund Accelerate Blue halfway toward its $2m initial target.

Mastercard will buy financial data technology provider Finicity in a deal that could reach $985m, giving Experian an exit. This is yet another large exits in this space this year after the acquisitions of Plaid and Credit Karma earlier.

Oncology treatment developer Relay Therapeutics is advancing research from several universities and has now filed for a $200m IPO.

The UCL and Ludwig Institute-linked cancer immunotherapy developer has raised more than $200m in funding and has filed to raise up to $100m.

Sethuraman Panchanathan has been appointed the new director of the US National Science Foundation, having previously held executive positions at ASU.

Gilead Sciences will invest $275m for a 49.9% stake in the UofT and UCSF-linked company as part of a $1.47bn deal to potentially purchase Pionyr outright.

Sana Biotechnology has closed its first round with more than $700m after investors including GV swung behind its vision to commercialise cell therapies.

Endowments for Harvard and Princeton have participated in Material Impact’s second fund, which closed at $200m after being oversubscribed.

OUP-backed utility customer data provider Urjanet has added $14.7m to its coffers.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Repare Therapeutics, which is commericalising precision cancer drugs based on research at UofT and NYU, added $33m to its IPO after its shares rose 65% post-offering.